@ANACONDAFINANC1 @dhovekamp42 @Getoutofmyway1 24+ ATEZO will be safe and effective who tried all these options. TEAEs were associated with dose reduction in 22% of patients (18/81) and with dose interruption in 37% of patients (30/81). TEAEs were associat
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @aminfield: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @aminfield: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer | Cancer Discovery | American Association for Cancer Research https://t.co/VrtoMWwDJk
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by Pasi Janne and colleagues https://t.co/pOvVDS2mxq @DanaFarber @DaiichiSankyoUS #Targets23 https://t.co/4iaF
RT @Pulmmed_CE: 14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@Da…
RT @Pulmmed_CE: 14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@Da…
14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFarber) ➡️ORR of 39% & mPFS of 8.2mos, w/confirmed clinical activity across a broad range of #HER3 membrane expression. 🔓https:
RT @onc_ce: 14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFa…
RT @onc_ce: 14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFa…
パトリツマブデルクステカン（HER3-DXd）、これだけ下向きに揃ってるウォーターフォールプロットを示してもORRが39%しか無いのか。最近チート級のトチ狂ったfig.しか見ないので、感覚が狂ってきた。
RT @onc_ce: 14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFa…
14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFarber) ➡️ORR of 39% & mPFS of 8.2mos, w/confirmed clinical activity across a broad range of #HER3 membrane expression. 🔓https:
RT @gasingiltv: What is the most effective approach to address the resistance mechanism to #osimertinib? Given the complex #EGFR_mutation p…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
What is the most effective approach to address the resistance mechanism to #osimertinib? Given the complex #EGFR_mutation pattern, wouldn't multiplayer be necessary? #HER3_Dxd resides in my mind. https://t.co/PeW97ElaGF by Pasi A. Jänne #WCLC2022 https://
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated No…
ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by Pasi Janne and colleagues @DanaFarber @DaiichiSankyoUS #WCLC22 https://t.co/1Sxx1ZRtvl https://t.co/IK1beUN
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer - PubMed https://t.co/WdIsQ5PiMi
RT @ElizSMcKenna: @IbiayiMD mentions the initial @CD_AACR paper on patritumumab deruxtecan (HER3-DXd) in her #ASCO22 Lung Cancer Poster Dis…
RT @ElizSMcKenna: @IbiayiMD mentions the initial @CD_AACR paper on patritumumab deruxtecan (HER3-DXd) in her #ASCO22 Lung Cancer Poster Dis…
RT @ElizSMcKenna: @IbiayiMD mentions the initial @CD_AACR paper on patritumumab deruxtecan (HER3-DXd) in her #ASCO22 Lung Cancer Poster Dis…
RT @ElizSMcKenna: @IbiayiMD mentions the initial @CD_AACR paper on patritumumab deruxtecan (HER3-DXd) in her #ASCO22 Lung Cancer Poster Dis…
@IbiayiMD mentions the initial @CD_AACR paper on patritumumab deruxtecan (HER3-DXd) in her #ASCO22 Lung Cancer Poster Discussion https://t.co/1Sxx2094TV https://t.co/G7EAaIB3b8
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
RT @ElizSMcKenna: Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deru…
Watching the #AACR22 session on Novel #AntibodyDrugConjugates? ICYMI in @CD_AACR: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated NSCLC by Pasi Janne and colleagues @DanaFarber @DaiichiSankyoUS https://t
RT @ElizSMcKenna: Here are the cited @CD_AACR studies: TDXd in HER2+ NSCLC https://t.co/gCVrzcmvzY HER3 DXd in EGFR-mut NSCLC https://t.c…
RT @ElizSMcKenna: Here are the cited @CD_AACR studies: TDXd in HER2+ NSCLC https://t.co/gCVrzcmvzY HER3 DXd in EGFR-mut NSCLC https://t.c…
Here are the cited @CD_AACR studies: TDXd in HER2+ NSCLC https://t.co/gCVrzcmvzY HER3 DXd in EGFR-mut NSCLC https://t.co/S72lKVKzgq
RT @cancer_evolve: LUNG: an ERBB3 targeted antibody-drug conjugate delivered ORR 39% in patients with EGFR-mutant lung cancer who have fail…
LUNG: an ERBB3 targeted antibody-drug conjugate delivered ORR 39% in patients with EGFR-mutant lung cancer who have failed EGFR therapy; EGFR mutant lung cancers are known to overexpress ERBB3 (also known as HER3). https://t.co/FzD30JqTYp
From the January issue: Efficacy and Safety of Patritumab Deruxtecan (#HER3-DXd) in #EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell #LungCancer by Pasi Janne and colleagues @DanaFarber @DaiichiSankyoUS. https://t.co/fPVv6M8n2Y https://t.co/QntIWbYVp
HER3-DXdは既知および未知のEGFR TKI耐性メカニズム横断的に臨床活性を示した https://t.co/6fxa6J6Lfg
RT @gedefo_sefh: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Canc…
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer [Research Articles] https://t.co/nmadHprFDj
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol https://t.co/7…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @DDNewsOnline: #FDA grants Breakthrough status to @DaiichiSankyo’s #patritumab deruxtecan vs #EGFR-mutated #NSCLC progressing despite 3r…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
EGFR（つまりERBB1）変異肺癌にERBB3に対するADCというのが直感に反するけど、EGFR-TKI抵抗性EGFR非小細胞肺癌にHER3-DXd（パトリツマブデルクステカン）がそのうち承認されそう
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer https://t.co/muNr6U0QCk
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
RT @NReguart: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer…
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer | Cancer Discovery https://t.co/SW0tvok3n4
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @MLPOncoData: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Canc…
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer https://t.co/Ia2LxA4v9s https://t.co/MQ7GQD6zou
RT @ElizSMcKenna: ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
ICYMI in @CD_AACR: the phase I trial of patritumab deruxtecan in EGFR-mutant NSCLC https://t.co/hwNJqReWol
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…
RT @StephenVLiu: Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-dru…